Advertisement
Screener

Syndax Pharmaceuticals, Inc. (SNDX) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Syndax Pharmaceuticals, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Syndax Pharmaceuticals, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $322.98M went out.
  • Fiscal year ended 2025-12-31: from investing, $290.04M came in.
  • Fiscal year ended 2025-12-31: from financing, $13.68M came in.
  • Fiscal year ended 2025-12-31: change in cash, $19.27M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDebt paid backNew debtNew shares soldOtherNot split outChange in cash
2025-12-31-$322.98M$290.04M$12.14M$1.54M*-$19.27M
2024-12-31-$274.90M-$219.78M$8.00M$345.37M*-$141.31M
2023-12-31-$160.60M$117.61M$5.13M$259.00M*$221.14M
2022-12-31-$133.68M-$186.19M$11.46M$160.79M*-$147.61M
2021-12-31$29.13M-$40.87M$6.34M$0.00$112.13M*$106.72M
2020-12-31-$71.26M-$142.53M$6.63M$1.00K$297.79M*$90.63M
2019-12-31-$50.61M$12.78M$178.00K$28.39M*-$9.26M
2018-12-31-$68.53M$51.40M$26.00K$8.00K$15.70M*-$1.40M
2017-12-31-$47.37M-$17.07M$277.00K$75.44M*$11.28M
2016-12-31-$35.16M-$18.28M$2.06M-$4.00K$52.15M*$762.00K
2015-12-31-$2.43M-$61.67M-$9.00M$191.00K-$2.00K$86.08M*$13.17M
2014-12-31-$14.39M$1.89M$14.00M$6.00K-$2.00K-$1.59M*-$95.00K

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldOtherNot split outChange in cash
2026-06-30-$30.27M*-$16.91M*$8.76M*$244.01M*
2026-03-31-$50.34M$38.39M$7.46M-$4.04M
2025-12-31-$69.49M*$81.58M*$5.31M*$605.00K*
2025-09-30-$70.53M*$72.43M*$6.36M*
2025-06-30-$87.80M*$41.89M*$83.00K*
2025-03-31-$95.16M$94.14M$385.00K$545.00K*-$90.00K
2024-12-31-$57.39M*-$268.97M*$3.14M*$344.29M*
2024-09-30-$62.32M*$86.85M*$2.56M*$535.00K*
2024-06-30-$71.64M*$61.75M*$439.00K*
2024-03-31-$83.55M-$99.40M$1.86M-$180.78M
2023-12-31-$41.35M*-$16.29M*$112.00K*$258.37M*
2023-09-30-$44.65M*$40.08M*$1.59M*
2023-06-30-$35.37M*$73.91M*$1.15M*
2023-03-31-$39.23M$19.91M$2.28M-$16.84M
2022-12-31-$22.89M*-$137.63M*$1.40M*$162.11M*
2022-09-30-$28.54M*-$6.79M*$0.00*-$13.53M*
2022-06-30-$40.31M*-$49.95M*$2.23M*$19.48M*
2022-03-31-$41.93M$8.18M$465.00K-$33.19M
2021-12-31$100.71M*-$59.96M*$3.02M*$106.75M*
2021-09-30-$24.94M*$26.63M*$0.00*$1.71M*
2021-06-30-$24.05M*$21.68M*$825.00K*$5.20M*
2021-03-31-$22.59M-$29.23M$881.00K-$50.86M
2020-12-31-$15.63M*-$64.14M*$3.57M*$135.09M*
2020-09-30-$18.30M*$19.27M*$1.71M*
2020-06-30-$21.41M*-$78.61M*$1.01M*$107.99M*
2020-03-31-$15.93M-$19.05M$338.00K$54.66M*$20.02M
2019-12-31-$12.73M*$6.60M*$0.00*
2019-09-30-$8.53M*$12.36M*$53.00K*
2019-06-30-$12.53M*-$18.93M*$45.00K*
2019-03-31-$16.83M$12.75M$27.00K-$2.00K$28.40M*$24.35M
2018-12-31-$15.04M*$15.96M*$0.00*$17.00K*$6.13M*
2018-09-30-$18.47M*$3.51M*$0.00-$8.00K*$9.47M*
2018-06-30-$15.15M*$19.28M*$26.00K$0.00*
2018-03-31-$19.87M$12.64M$34.00K-$1.00K-$7.19M
2017-12-31-$12.72M*$1.55M*$1.00K*$25.61M*$14.44M*
2017-09-30-$10.18M*$6.92M*$7.00K*-$1.00K*$998.00K*-$2.26M*
2017-06-30-$11.80M*-$36.51M*$151.00K*$0.00*$48.84M*$632.00K*
2017-03-31-$12.67M$11.01M$118.00K-$1.00K-$1.54M
2016-12-31-$10.42M*$21.33M*$206.00K*-$1.00K*$11.09M*
2016-09-30-$11.45M*$8.05M*-$1.00K*$1.71M*-$1.69M*
2016-06-30-$6.89M*-$624.00K*-$1.00K*-$1.23M*-$8.75M*
2016-03-31-$6.40M-$47.14M-$1.00K$53.55M*$8.00K
2015-12-31-$4.29M*-$17.56M*$11.00K*$0.00*-$9.19M*-$31.04M*
2015-09-30-$5.18M*-$7.41M*$168.00K*-$1.00K*$59.89M*$47.47M*
2015-06-30-$4.00M*-$17.21M*$18.68M*-$2.53M*
2015-03-31$11.04M-$19.48M$7.71M*-$727.00K

Similar stocks

Stock NameCountryMarket CapPE Ratio
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Innoviva, Inc. (INVA)United States$1.493B4.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50